Russia

Russia remains a tightly controlled market for classical psychedelics. Federal narcotics rules place psilocybin, psilocin, mescaline, LSD and DMT-containing materials in the prohibited lists, which means access is generally confined to sanctioned medical or research settings rather than routine care.

Ask Blossom about this country

Key Insights

A concise read of the policy, research, and stakeholder signals shaping psychedelic medicine in Russia.

1
Russia's psychedelic policy is best described as prohibition outside tightly controlled medical or research contexts, rather than a permissive or decriminalised model.
2
Ketamine is the main clinically relevant exception and has a documented Russian research lineage, especially in addiction treatment and peri-operative care.
3
The strongest Russian research signal linked to Blossom's themes is ketamine work in opioid dependence, including a randomised trial from St Petersburg.
4
Recent clinical-trial material still references Russian investigators and sites in ketamine studies, suggesting ongoing institutional capability even though Blossom currently has no active linked trials.
5
No solid source located here supports routine patient access to psilocybin- or MDMA-based therapy, so any such claim would be high risk.

Research Snapshot

Blossom currently tracks 2 psychedelic clinical trials connected to Russia.

Active trials: 0
Total trials: 2
Stakeholders: 0
Events: 0

Top Compounds

Ketamine(2)

Medical Access Snapshot

Russia maintains a restrictive, control-focused regime for classical psychedelics: most tryptamines, phenethylamines and seeded plant/tea preparations containing DMT or psilocybin are prohibited outside of sanctioned research, while ketamine is an accepted and registered medical anesthetic (and appears on national essential medicines lists). There is no broad, reimbursed medical psychedelic therapy program (no public insurance coverage for psilocybin/MDMA therapies or for esketamine as an antidepressant is not registered), and authorized access is...

View trials→Open access guide→

Regulatory Status

Medical access is restrictive and control-led. The Ministry of Health's narcotics list explicitly includes psilocybin, psilocin, mescaline, LSD, DMT-related materials and mushroom fruiting bodies containing psilocybin/psilocin among prohibited substances, while ketamine is separately registered as a medicine. That supports legal medical ketamine use, but not broad legal access to psychedelic therapies; I found no reliable evidence of a public reimbursement pathway for psilocybin, MDMA or esketamine as an antidepressant in Russia, so that part should remain cautious.